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VG: Hello and welcome to the Diabetes
Therapy podcast. You are listening to the first
podcast in our Diabetic Neuropathy collection.
My name is Victoria Glasson and I am the Editor
for the journal and today we will be speaking to
Dr Uazman Alam, Senior Clinical Lecturer and
Honorary Consultant at Liverpool University
Hospital and esteemed member of the Diabetes
Therapy Editorial Board.
UA: Thank you Victoria, I’m as you stated, a
Senior Clinical Lecturer and Honorary Consul-
tant at Liverpool University Hospital. My back-
ground is very much in diabetic neuropathy
and lower limb disease in diabetes and I’m
really eager to speak about diabetic neuropathy
today.
VG: Fantastic, Uazman. Thank you. So to
start off, could you please tell us what is diabetic
neuropathy?
UA: Sure, so diabetes affects the peripheral
nervous system and essentially diabetic neu-
ropathy is a disorder of the peripheral nervous
system which occurs due to the underlying
diabetes and leads to peripheral nerve dysfunc-
tion and it’s actually the commonest compli-
cation of diabetes. It affects anywhere up to
50% of people with type 1 and type 2 diabetes
[1, 2]. In fact, looking at the prevalence studies
out there, there is even a suggestion that it may
affect a lot more [depending on patient popu-
lation] [3].
VG: What are the signs and symptoms that
people should look out for?
UA: So the commonest symptoms tend to be
those that are sensory in nature so patients can
often complain of pain and can also complain
of other kinds of what we call positive symp-
toms. Those are symptoms of pain and for
instance burning; they can complain of
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shooting pain. These are typical positive symp-
toms. Then we have the negative symptoms
which actually tend to be again distributed in
the same area which can occur in the glove and
stocking distribution in the distal areas in the
feet and the hands. The negative symptoms
often can be comprised of numbness kind of
feelings or sensations [2].
So those are the initial symptoms that people
can complain of, but as the disease progresses
then you can get what we call motor [system]
involvement and that is actually weakness and
you can get weakness that occurs in more distal
areas [weakness is closely related to signs and
severity of diabetic neuropathy]. It occurs more
proximally with the progress of time and as
symptoms progress [increasing severity]. And
on the flip side of this, there is also autonomic
symptoms as well and these tend to only pre-
sent quite late on the disease course. When I
mean autonomic symptoms, I mean those that
may involve the cardiovascular, gastrointestinal
or genitourinary systems and include sweat
glands. [Cardiac] Autonomic symptoms tend
not to occur in the early stages of autonomic
neuropathy [which can be detected by cardiac
autonomic testing].
VG: What is the most common type of dia-
betic neuropathy?
UA: So this would be diabetic peripheral
neuropathy, also known as distal symmetrical
polyneuropathy. So this is what I mentioned
before, the glove and stocking distribution of
neuropathy of nerve damage, and this tends to
be the commonest form, although autonomic
neuropathy is extremely common as well.
VG: How is diabetic neuropathy prevented?
UA: I’m going to have to split this into
thinking about diabetic neuropathy in terms of
type 1 diabetes and type 2 diabetes. So in type 1
diabetes we have shown that actually having
really good glycaemic control can prevent or
actually halt the progression of diabetic neu-
ropathy [4], but the jury is somewhat out with
type 2 diabetes and a number of studies have
actually shown that glucose control by itself
may not affect the prevention or the progres-
sion of diabetic neuropathy [5]. So in type 2
diabetes we really think of this as a more mul-
tifactorial kind of treatment. In general, we
should be telling our patients to control the
diabetes and try to improve the cardiovascular
risk co-factors including the lipids, triglycerides,
hypertension [and weight] [6]. There is some
data that suggests that if you are heavier you
might have more painful symptoms [and is also
a risk factor for diabetic neuropathy] [7, 8], so
again those individuals with type 2 diabetes is
really an improvement in the weight. Again,
diet and exercise, avoid excess alcohol, and of
course it’s really one of the most paramount
things we can ask them to do is to stop smoking
as well.
VG: Can you take us through the reasons
why some people have pain despite a normal
examination or no signs of neuropathy?
UA: We need to think about the actual ner-
vous system itself when we think about people
who have a normal examination and have no
signs of neuropathy but they are still com-
plaining of symptoms and pain, so for instance
either burning pain or even numbness. So the
peripheral nervous system [grossly] comprises of
A-alpha, A-beta and A-delta fibres and also
C fibres. And it’s the C fibres or what’s also
known as the smaller [nerve] fibres that are
affected first. And these are the ones that are
involved in the generation of pain and are
related to symptoms including that of burning.
So when we think about people who have dia-
betic neuropathy, it’s not just those individuals
that have quite severe disease with large [nerve]
fibre involvement [and subsequent signs of
diabetic neuropathy], but it’s those that actually
have small fibre deficits so this can actually
cause some quite considerable amounts of
symptoms and pain despite having a [poten-
tially] normal examination.
VG: So why can diabetic neuropathic pain be
worse at night?
UA: Diabetic neuropathy pain is worse at
night and this is quite typical of neuropathic
pain itself, [including neuropathic pain that can
involve (results from) other areas of the
somatosensory system]. Why the pain is worse
at night still remains relatively unknown
although it was first described by Frederick
William Pavy in the nineteenth century [9].
There has been some suggestion that there may
be involvement in the locus coeruleus which is
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thought to play a part in pain and also sleep,
but it remains unknown [in terms of its exact
contribution] [10, 11]. What we do know [about
the chronobiology of diabetic neuropathy] is
that there is increasing pain sensitivity later on
in the evening and at night and previous studies
have shown this [12, 13].
VG: So does this impact on sleep?
UA: It does have an impact on sleep and
people can often complain about waking up in
the night with painful symptoms and I see this
quite often in my clinic. So imagine you’re in
pain and the pain is worse at the time when you
are trying to go to sleep and not only that but it
wakes you up at night; this can often be quite
debilitating and have a major impact on the
quality of life of our patients [14].
VG: Is there a relationship between mood or
depression and painful diabetic neuropathy?
UA: Well we just need to think about sleep
itself. I’ve mentioned that sleep can be
impaired; if you aren’t sleeping very well and
you are in chronic pain then you tend to have a
worse mood and you are more likely to be
depressed. Now unfortunately if you are
depressed or have a low mood then you are
more likely have painful symptoms. So this can
be somewhat of a vicious cycle which, if you
can break the cycle then you can get improve-
ments in both the mood and the pain.
There was a study which was published in
2005 by Gore et al. [14] which quite clearly
showed that the increasing levels of pain, then
the more likely to have anxiety and also
depression and the higher levels of these, so
really the more pain you are in the more likely
people are to have anxiety and depression.
VG: Which autonomic dysfunctions must be
managed in patients?
UA: So it’s really important for us to under-
stand that autonomic dysfunction can occur
relatively early on in the disease course and [in
the later stages of the disease] it can have a
major impact on the quality of life. So the one
major autonomic dysfunction that can occur is
erectile dysfunction and it’s really important
that we ask male patients about erectile dys-
function and this can have a major effect on the
quality of life. Also, there’s gustatory sweating
and there are treatments which are available
which are off-label for gustatory sweating. I
have used glycopyrrolate paste [15] or solife-
nacin or even oxybutynin [NICE Evidence
Summary—ES10] [16] [all three treatments are
off-label for hyperhidrosis] to try and get some
improvement in gustatory sweating and it can
have a major impact on the quality of life.
Imagine if you are going out for a family meal or
a meal with friends and as you eat you are
profusely sweating. It can have major implica-
tions in social exclusion.
VG: Is there a way that we can reverse auto-
nomic neuropathy?
UA: There are some data that suggest that
autonomic neuropathy can be reversed in the
early stages [17]. Once you have got to ortho-
static hypotension or where people are having
postural hypertension then it’s quite late on in
the disease, so then it’s not really reversible [18].
But there is some data to suggest that there can
be some reversibility particularly with diet and
exercise [19]. Unfortunately, we don’t have any
treatments that affect the pathogenesis of dia-
betic neuropathy or even autonomic
neuropathy.
VG: What happens to the quality of life of
the patients [with diabetic neuropathy]?
UA: Well we just need to imagine the various
aspects of diabetic neuropathy. So one I’ve
mentioned, pain; the co-morbidities that
include anxiety, depression and also lack of
sleep or sleep interference. And this would all
affect people’s quality of life; it can be really
quite detrimental.
VG: What kind of information should people
suffering with diabetic neuropathy be given?
UA: We should really be educating patients
on all aspects of diabetic neuropathy, so this
includes the importance of glycaemic control in
addition to improving the cardiovascular risk
co-factors. In the early stages of diabetes it is
really important to try to achieve good control
of glycaemia and also to modify any risk factors.
Importantly we should be telling people to stop
smoking [if they smoke], and if people do have
diabetic neuropathy and subsequently have
symptoms of pain then they do need to be
informed that we are unlikely to achieve 100%
pain relief with any treatment; at best what we
are aiming for is 50% pain relief [20]. But as a
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part of our consultation we should be coun-
selling patients in regards to all of these varying
factors.
VG: Is there anything that we can do to
prevent neuropathic diabetic foot ulcers?
UA: That’s an excellent question. So diabetic
neuropathy is the strongest risk factor for foot
ulceration and amputation in people with dia-
betes. As a rule of thumb, those individuals that
do have diabetic neuropathy, more so particu-
larly those that have severe neuropathy, need to
undergo daily foot examinations. Those that
have insensate feet and a lack of sensation really
need to emphasize the importance of foot care
and protection, i.e. not to walk barefoot. They
need to consider how they trim their toenails
and to do this with great care and actually have
podiatry input for this, and of course think
about foot hygiene and look out for any kind of
infection in the feet. And again, another really
important aspect is the need for wearing well-
fitted shoes and not to wear sort of hard-soled
shoes where they are walking long distances in
this, and of course there is trying to gain advice
on footwear early on [21].
VG: What are the main risk factors for
developing diabetic neuropathy? Is age a big
factor?
UA: So age is a risk factor but that is some-
what in relation to the duration of the diabetes.
So the longer the duration of diabetes then the
more likely you are to have diabetic complica-
tions or diabetic neuropathy. So you can say as a
rule of thumb by about 25 years’ duration of
diabetes, about half of the population will have
diabetic neuropathy. There have been other
associated factors such as hypertriglyceridemia,
hypertension, weight which have all also been
linked to diabetic neuropathy.
VG: We are going to be discussing diabetic
neuropathy treatments in depth in another
podcast but can you quickly talk us through the
treatments for different types of neuropathy?
UA: So the mainstay of treatment for all the
diabetic neuropathies, whether this is auto-
nomic, distal symmetrical or even if it’s another
form of diabetic neuropathy, is really try to
improve glycaemic control along with the car-
diovascular risk factors. Of course, stopping
smoking which I have said a number of
occasions but that remains really the mainstay
of therapy in trying to prevent or trying to halt
the progression. Now each individual type of
neuropathy will have its own treatment. So for
instance diabetic peripheral neuropathy [has
specific treatments]. We have talked about pain
and we will be talking about pain relief in terms
of neuropathic agents, but for instance with
autonomic neuropathy we need to consider the
various aspects of autonomic neuropathy whe-
ther this is cardiac autonomic, whether it’s
erectile dysfunction or say for instance gastro-
paresis and we’d treat each of those for symp-
toms. So erectile dysfunction you can consider
phosphodiesterase inhibitors or other kinds of
erectile dysfunction measures. Again, testos-
terone can be low in people with erectile dys-
function, so this may be something that we
need to look at on an individual basis particu-
larly people with type 2 diabetes.
Gastroparesis can be quite difficult to treat
and there is a number of different therapies that
can be used, but these are mainly off-label
[domperidone, azithromycin, erythropmycin].
Cardiac autonomic neuropathy again is gener-
ally quite asymptomatic in the early stages and
only becomes symptomatic later on, but if we
are thinking about orthostatic hypotension
then there is all the various therapies that are
available for the treatment which include flu-
drocortisone, midodrine and again other off-
label therapies such as pyridostigmine and
ephedrine as well as abdominal binders [similar
to compression stockings].
VG: Finally, you’ve mentioned counselling
for patients; is this something patients do have
access to and that they can utilise?
UA: Sure. So when I say counselling of
patient, I mean this is counselling within our
own clinics; so this is something that each
clinician should be doing. So what are the
expectations that each patient has and what are
we able to do for the patient in terms of these
expectations? We should be counselling
patients every time we meet them in clinic, but
in terms of formal psychology counselling the
access to this can be quite variable actually; so it
depends on where you work, particularly in the
UK. So I’m quite lucky that we have access to
specific pain counsellors and psychologists and
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also diabetes psychologists, and they are really a
very helpful resource and should be utilised
[when needed]. So I tend to refer people who are
having management problems with their dia-
betes [i.e. significant diabetes distress] and in
particular those that are in quite severe pain as
well I would refer to the pain psychologist and
patients have received quite significant benefits
from seeing these individuals [health
professionals].
VG: Uazman thank you so much for taking
the time to speak to us today. As I mentioned at
the start of the podcast we will be releasing
another two podcasts in our Diabetic Neuropa-
thy collection focusing on diagnosis, and then
another focusing on treatment. Again Uazman,
thank you so much.
UA: Thank you, Victoria.
You can listen to more podcasts by sub-
scribing to Adis Rapid? podcasts with your
preferred podcast provider, or by visiting the
website. Please note, (parentheses) represent
additional information not mentioned in the
podcast that has been added into the transcript
by the authors for transparency.
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